ClinicalTrials.gg
CompletedNCT01169090Updated Aug 17, 2011

A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy

A Phase 2 interventional study of SK-0403 and Placebo in Type 2 Diabetes, sponsored by Kowa Research Institute, Inc.. Completed at 40 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-08-17.

Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
620
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Planned enrollment
348th of 2,957
620 · median 90
Started
2010
with 166 others
Phase 2
391 of 3,304
24 open now
Registered
978th of 3,304
by date

Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 348th largest by planned enrollment of the 2,957 interventional ones that give a count, is one of 167 that started in 2010, is one of 391 in phase 2, and was the 978th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

338 more — sign in →

All 343 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of a range of doses of SK-0403 in subjects with type 2 diabetes that are not adequately controlled on metformin alone.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects with type 2 diabetes between 18 and 75 years of age, inclusive
  • Screening between 7.0% to 10.0% for metformin stable subjects, 6.5% to 9.0% for subjects on metformin and 1 other antidiabetic agent (excluding thiazolidinediones, insulin, or incretin therapies [DPP-4 inhibitors and GLP-1 analogues]), or 7.5% to 11.0% for subjects on no antidiabetic medication or, if taking metformin, not on a stable dose of 1500 mg/day or maximum tolerated dose.
  • No antidiabetic medication other than metformin for 3 months prior to randomization.
  • Fasting plasma glucose less than 270 mg/dL (15 mmol/L) at screening.
  • between 20 kg/m2 and 45 kg/m2 inclusive at screening.

Exclusion criteria

Exclusion Criteria:

  • History of type 1 diabetes.
  • Received treatment with insulin within 30 days of the screening visit or for more than 1 week within 3 months of the screening visit.
  • Use of 3 or more oral antidiabetic medications at the time of the screening visit.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
620 participants (estimated)

Study arms

  • Experimental
    SK-0403 100 mg QD

    Drug: SK-0403

  • Experimental
    SK-0403 200 mg QD

    Drug: SK-0403

  • Experimental
    SK-0403 400 mg QD

    Drug: SK-0403

  • Experimental
    SK-0403 200 mg BID

    Drug: SK-0403

  • Sham comparator
    Placebo

    Drug: Placebo

  • Active comparator
    Sitagliptin 100 mg QD

    Drug: Sitagliptin

Interventions

06

What researchers measure

Primary outcomes

  1. Change in HbA1c from baseline to Week 16.

    Change in HbA1c from baseline to Week 16 with last observation carried forward (LOCF).

    Time frame: Baseline, 16 weeks

Secondary outcomes

  1. Change from baseline in Fasting Plasma Glucose (FPG)

    Time frame: Baseline, 16 weeks

07

Study locations

40 sites
  • Birmingham, Alabama, United States
  • Huntsville, Alabama, United States
  • Muscle Shoals, Alabama, United States
  • Phoenix, Arizona, United States
  • Encinitas, California, United States
  • Huntington Park, California, United States
  • Los Angeles, California, United States
  • San Mateo, California, United States
  • Spring Valley, California, United States
  • Walnut Creek, California, United States
  • Miami, Florida, United States
  • Palm Harbour, Florida, United States
  • Pembroke Pines, Florida, United States
  • Honolulu, Hawaii, United States
  • Chicago, Illinois, United States
  • Indianapolis, Indiana, United States
  • Lexington, Kentucky, United States
  • Paducah, Kentucky, United States
  • New Orleans, Louisiana, United States
  • St. Paul, Minnesota, United States
  • Charlotte, North Carolina, United States
  • Greenville, North Carolina, United States
  • Statesville, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Marion, Ohio, United States
  • Mount Giliad, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Eugene, Oregon, United States
  • Portland, Oregon, United States
  • Beaver, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Greensboro, South Carolina, United States
  • Corpus Christi, Texas, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Salt Lake City, Utah, United States
  • Sandy, Utah, United States
  • Norfolk, Virginia, United States
  • Richmond, Virginia, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Jul 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2010
First posted
Jul 23, 2010
Start
Jul 2010
Primary completionActual
Jul 2011
CompletionActual
Aug 2011
Last update
Aug 17, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01169090
First posted
Jul 23, 2010
Start date
Jul 2010
Primary completion
Jul 2011
Completion
Aug 2011
Last update
Aug 17, 2011

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anagliptin

Start the discussion